1 – 11 of 11
- show: 15
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2022
-
Mark
Real World Evaluation of the Prosigna/PAM50 Test in a Node-Negative Postmenopausal Swedish Population : A Multicenter Study
(
- Contribution to journal › Article
- 2021
-
Mark
Benefit of pazopanib in advanced gastrointestinal stromal tumours: results from a phase II trial (SSG XXI, PAGIST)
(
- Contribution to journal › Article
-
Mark
Neoadjuvant Trastuzumab, Pertuzumab, and Docetaxel vs Trastuzumab Emtansine in Patients with ERBB2-Positive Breast Cancer : A Phase 2 Randomized Clinical Trial
(
- Contribution to journal › Article
- 2020
-
Mark
Efficacy and safety of tailored and dose-dense adjuvant chemotherapy and trastuzumab for resected HER2-positive breast cancer : Results from the phase 3 PANTHER trial
(
- Contribution to journal › Article
- 2018
-
Mark
Dynamic evaluation of the immune infiltrate and immune function genes as predictive markers for neoadjuvant chemotherapy in hormone receptor positive, HER2 negative breast cancer
(
- Contribution to journal › Article
-
Mark
Long-term safety and survival outcomes from the Scandinavian Breast Group 2004-1 randomized phase II trial of tailored dose-dense adjuvant chemotherapy for early breast cancer
(
- Contribution to journal › Article
-
Mark
Immune gene expression and response to chemotherapy in advanced breast cancer
(
- Contribution to journal › Article
- 2017
-
Mark
PAM50 provides prognostic information when applied to the lymph node metastases of advanced breast cancer patients
(
- Contribution to journal › Article
-
Mark
An HIF-1α/VEGF-A Axis in Cytotoxic T Cells Regulates Tumor Progression
(
- Contribution to journal › Article
- 2016
-
Mark
Effect of tailored dose-dense chemotherapy vs standard 3-weekly adjuvant chemotherapy on recurrence-free survival among women with high-risk early breast cancer : A randomized clinical trial
(
- Contribution to journal › Article
- 2008
-
Mark
Array-CGH identifies cyclin D1 and UBCH10 amplicons in anaplastic thyroid carcinoma.
(
- Contribution to journal › Article